EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Finch Therapeutics Group's enterprise value is $33.83 Mil.
Finch Therapeutics Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Therefore, Finch Therapeutics Group's EV-to-Revenue for today is .
The historical rank and industry rank for Finch Therapeutics Group's EV-to-Revenue or its related term are showing as below:
FNCH'
s EV-to-Revenue Range Over the Past 10 Years
Min: -9.5 Med: 29.95 Max: 283.9
Current: 316.16
During the past 5 years, the highest EV-to-Revenue of Finch Therapeutics Group was 283.90. The lowest was -9.50. And the median was 29.95.
FNCH's EV-to-Revenue is ranked worse than 92.15% of 994
companies
in the Biotechnology industry
Industry Median: 7.16
vs FNCH: 316.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Finch Therapeutics Group's EV-to-Revenue
For the Biotechnology subindustry, Finch Therapeutics Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Finch Therapeutics Group's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's EV-to-Revenue falls into.
Finch Therapeutics Group's current Enterprise Value is $33.83 Mil.
Finch Therapeutics Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (OTCPK:FNCH) EV-to-Revenue Explanation
Finch Therapeutics Group's share price for today is $13.00.
Finch Therapeutics Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Finch Therapeutics Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FNCH has been successfully added to your 